Drugs / cetuximab N01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07581912 | Apr 2026 → Dec 2028 expected | colorectal cancer | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cetuximab N01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07581912 ↗ |
| Action | Inhibit | “anti-EGFR antibodies” NCT07581912 ↗ |
| Route | Intravenous | “cetuximab N01 (500 mg/m², IV, q2w)” NCT07581912 ↗ |
| Target | EGFR | “anti-EGFR antibodies” NCT07581912 ↗ |